Leerink Partnrs Issues Positive Estimate for Bruker Earnings

Bruker Co. (NASDAQ:BRKR) – Equities researchers at Leerink Partnrs increased their FY2024 EPS estimates for Bruker in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $2.39 for the year, up from their prior estimate of $2.38. The consensus estimate for Bruker’s current full-year earnings is $2.39 per share. Leerink Partnrs also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $2.74 EPS, FY2026 earnings at $3.16 EPS and FY2027 earnings at $3.65 EPS.

Several other analysts have also recently weighed in on BRKR. Barclays lowered their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Bank of America lifted their price target on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Friday, January 17th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a research note on Thursday, December 5th. Finally, UBS Group initiated coverage on shares of Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $74.45.

Bruker Trading Up 0.1 %

Shares of BRKR opened at $60.12 on Wednesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker has a 1-year low of $48.07 and a 1-year high of $94.86. The company has a market capitalization of $9.11 billion, a P/E ratio of 28.90, a P/E/G ratio of 3.32 and a beta of 1.17. The firm’s 50 day simple moving average is $57.96 and its 200 day simple moving average is $61.61.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.74 earnings per share.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.33%. The ex-dividend date was Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is 9.62%.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of the company’s stock in a transaction on Monday, November 18th. The stock was acquired at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This represents a 0.26 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 28.30% of the stock is currently owned by company insiders.

Institutional Trading of Bruker

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. True Wealth Design LLC increased its position in Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares during the period. Eagle Bay Advisors LLC boosted its stake in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. increased its position in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd bought a new position in Bruker in the second quarter worth about $52,000. Finally, GAMMA Investing LLC lifted its holdings in Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.